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ABSTRACT
Skeletal muscle wasting in facioscapulohumeral muscular dystrophy
(FSHD) results in substantial morbidity. On a disease-permissive
chromosome 4qA haplotype, genomic and/or epigenetic changes at
the D4Z4 macrosatellite repeat allows transcription of the DUX4
retrogene. Analysing transgenicmice carrying a humanD4Z4 genomic
locus from an FSHD-affected individual showed that DUX4 was
transiently induced in myoblasts during skeletal muscle regeneration.
Centromeric to the D4Z4 repeats is an inverted D4Z4 unit encoding
DUX4c. Expression of DUX4, DUX4c and DUX4 constructs, including
constitutively active, dominant-negative and truncated versions,
revealed that DUX4 activates target genes to inhibit proliferation and
differentiation of satellite cells, but that it also downregulates target
genes to suppress myogenic differentiation. These transcriptional
changes elicited by DUX4 in mouse have significant overlap with
genes regulated by DUX4 in man. Comparison of DUX4 and DUX4c
transcriptional perturbations revealed that DUX4 regulates genes
involved in cell proliferation, whereas DUX4c regulates genes
engaged in angiogenesis and muscle development, with both DUX4
and DUX4c modifing genes involved in urogenital development.
Transcriptomic analysis showed that DUX4 operates through both
target gene activation and repression to orchestrate a transcriptome
characteristic of a less-differentiated cell state.
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INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD) is autosomal
dominant, characterised by descending, often asymmetric,
skeletal muscle weakness and wasting, starting with facial, shoulder
and proximal upper limb muscles (Tawil and Van Der Maarel, 2006).
FSHD has an incidence of ∼1:15,000 (Flanigan et al., 2001) and
prevalence of 1 in 8333 to 1 in 20,000 (Deenen et al., 2014; Padberg
et al., 1995).
Satellite cells are responsible for maintenance and repair of
skeletal muscle (Relaix and Zammit, 2012), and muscle dystrophy
implies a failure of this normal homeostatic and repair function
(Morgan and Zammit, 2010). Consistent with this premise,
myoblasts from FSHD-affected individuals are more susceptible
to oxidative stress and show deregulation ofMYOD (also known as
MYOD1) (Winokur et al., 2003a,b), and differentiate into myotubes
with abnormal morphology (Barro et al., 2008).
In 95% of FSHD cases (FSHD1; OMIM158900), a contraction
to 1–10 units and CpG-DNA hypomethylation of the highly
polymorphic D4Z4 repeat region in the subtelomere of chromosome
4q occurs (van Deutekom et al., 1993; van Overveld et al., 2003;
Wijmenga et al., 1992). Each D4Z4 repeat contains an open reading
frame (ORF) for Double homeobox 4 (DUX4) (OMIM606009)
(Gabriels et al., 1999; Hewitt et al., 1994), and DNA-CpG
hypomethylation is associated with DUX4 transcription from the
D4Z4 units, which are usually somatically repressed (Dixit et al.,
2007). A polymorphism in disease-permissive 4qA haplotypes
provides a polyadenylation signal for DUX4 transcripts emanating
from the final D4Z4 unit (Lemmers et al., 2010). The remaining 5%
(FSHD2; OMIM158901) have no contraction of the D4Z4 repeats
but still exhibit CpG-DNA hypomethylation of D4Z4 units and also
carry a permissive 4qA allele. Most FSHD2 individuals have
mutations in the chromatin-modifying protein SMCHD1 (Lemmers
et al., 2012), whereas others have mutations in the DNA
methyltransferase DNMT3B (van den Boogaard et al., 2016).
Although altered expression of non-coding RNAs (Cabianca et al.,
2012) and neighbouring 4q genes – e.g. FRG1 (Gabellini et al., 2006)
and mutations in FAT1 (Caruso et al., 2013) – have also been
implicated in FSHD, there is growing consensus that aberrant
expression of DUX4 underlies pathogenesis in both FSHD1 and
FSHD2, actingwith again-of-functionmechanism(Tawil et al., 2014).
DUX4 mRNA and/or protein can be detected in FSHD-
individual-derived proliferating myoblasts, with levels increasing
during differentiation and sporadic expression in rare nuclei of
myotubes (Dixit et al., 2007; Jones et al., 2012; Kowaljow et al.,
2007; Snider et al., 2010; Tassin et al., 2013). A DUX4 reporter
reveals that DUX4 is transcriptionally active in FSHD-derived
proliferating myoblasts, which becomes more widespread upon
myogenic differentiation (Rickard et al., 2015).
D4Z4 tandem repeats andDUX4ORFare evolutionarily conserved
in placental mammals (Clapp et al., 2007; Giussani et al., 2012).
Identification of DUX proteins in germline cells (Geng et al., 2012)
suggests a role during development, but little is known of endogenous
DUX4 function. Two important DUX4 isoforms are derived from the
D4Z4 ORF –DUX4-fl (full-length) that is expressed in germline and
stem cells, and the alternatively spliced DUX4-s (short) isoform
expressed in some somatic cells at low levels (Snider et al., 2010).
Mice transgenic for a D4Z4 repeat array from an FSHD
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contracted FSHD locus. DUX4 is expressed in germline cells, and
the protein can be detected in myoblasts and muscle, but there is no
overt skeletal muscle pathology (Krom et al., 2013). Ectopic DUX4
expression results in impaired myogenesis (Dandapat et al., 2014)
and gross muscle damage through p53-dependent apoptosis in other
mouse models (Wallace et al., 2010).
How incomplete repression of DUX4 in somatic cells causes
muscular dystrophy is enigmatic. DUX4 inhibitsmuscle differentiation
and induces myoblast death (Bosnakovski et al., 2008a; Kowaljow
et al., 2007). DUX4 also causes myoblasts to differentiate to produce
myotubeswith amorphologysimilar to the dysmorphicmyotubes from
FSHD individuals (Vanderplanck et al., 2011). However, systematic
comparison is lacking between DUX4, DUX4c and DUX4-s.
DUX4 is a transcription factor. The N-terminus contains two
homeodomains with similarity to those of PAX3 and PAX7
(Bosnakovski et al., 2008b), and the C-terminus is a transcriptional
activator (Kawamura-Saito et al., 2006). FSHD muscle biopsies
and DUX4-expressing myoblast cultures indicate perturbation of
Wnt–β-catenin signalling, MYOD regulation, oxidative stress and
innate immune response (Banerji et al., 2015a; Block et al., 2013;
Bosnakovski et al., 2008a; Celegato et al., 2006; Fitzsimons, 2011;
Geng et al., 2012; Winokur et al., 2003b). Transcriptome analysis of
endogenous DUX4-expressing cells reveals that DUX4 disrupts
pathways involved in RNAmetabolism, cell signalling, polarity and
migration (Rickard et al., 2015), and nonsense-mediated decay
(Feng et al., 2015).
Mutation of a DUX4 homeodomain or competitive inhibition by
shortened DUX4 splice variants inhibits DUX4 target gene
activation and abrogates DUX4-induced cell death (Ferri et al.,
2015; Geng et al., 2012; Mitsuhashi et al., 2013; Wallace et al.,
2010). Although DUX4 binding motifs have been identified (Dixit
et al., 2007; Ferri et al., 2015; Geng et al., 2012; Young et al., 2013;
Choi et al., 2016), and ChIP-Seq performed (Geng et al., 2012; Choi
et al., 2016), a set of target genes that explains both anti-myogenic
and apoptotic phenotypes induced by DUX4 has not been
comprehensibly defined.
An incomplete and reversedD4Z4unit is located 40 kb centromeric
to the D4Z4 repeat array. This encodes DUX4c, which lacks the N-
terminus and diverges from DUX4-fl in the C-terminal region but is
otherwise homologous to DUX4-fl. DUX4c is detectable in FSHD
muscle biopsies and FSHD-derived proliferating myoblasts, and
increases in myotubes (Ansseau et al., 2009).
Here, we show that DUX4 is transiently elevated in myoblasts
during muscle regeneration. To model FSHD, we used retroviral-
mediated delivery of DUX4, in parallel with truncated, constitutively
active anddominant-negativeDUX4versions, aswell aswithDUX4c.
DUX4 activates transcriptional targets to suppress proliferation in
satellite cells but can both activate and inhibit transcriptional targets to
preventmyogenic differentiation. Transcriptomic analysis showed that
DUX4 acts as a strong transcriptional activator but can also inhibit
transcriptional targets. DUX4c increases transcription of some genes
that are induced byDUX4 but also repressed a significant proportion.
In general, DUX4 orchestrates a transcriptomemore characteristic of a
less-differentiated cell state.
RESULTS
DUX4 is transiently expressed during skeletal muscle
regeneration
Two transgenic mouse models for FSHD have been previously
generated – control D4Z4-12.5 mice contain a human genomic
region encompassing 12.5 D4Z4 units, whereas FSHD1 D4Z4-2.5
mice are transgenic for a contracted human repeat with 2.5 D4Z4
units obtained from an FSHD-affected individual. D4Z4-2.5
transgenic mice reveal low and variable levels of DUX4 in
skeletal muscles (Krom et al., 2013).
We first screened DUX4 expression from the human transgenic
locus in D4Z4-12.5 (control) and D4Z4-2.5 (FSHD1) mice during
skeletal muscle regeneration in vivo. Gastrocnemius muscles of five
adult D4Z4-12.5 andD4Z4-2.5micewere injectedwith cardiotoxin to
induce muscle damage, with the contralateral side receiving saline. At
days 3, 4, 5, 6 and 10 post-injection, muscle regenerationwas analysed
by histological examination (Fig. 1A). Skeletal muscle in both D4Z4-
12.5 and FSHD1 D4Z4-2.5 mice successfully regenerated, consistent
with our previous observations (Krom et al., 2013).
Human DUX4, murine Duxbl, Myod and Myog (myogenin)
expression was measured using real time quantitative PCR (RT-
qPCR) on RNA extracted from the other half of the regenerating
gastrocnemius muscles (Fig. 1B; Fig. S1). Myog levels increased
during the early phase of muscle regeneration in both D4Z4-2.5 and
D4Z4-12.5 mice as expected. As shown previously (Wu et al.,
2014), substantial Duxbl levels were detectable in mouse skeletal
muscle, with levels enhanced during regeneration (Fig. S1A,B).
DUX4 levels were negligible but increased in gastrocnemius at days
4 and 5 post-cardiotoxin injection of D4Z4-2.5 mice, compared to
those in undamaged control muscles, before returning to pre-injury
levels at days 6–10 (Fig. 1B). RT-qPCR analysis was also
performed on RNA from further D4Z4-2.5 gastrocnemius
muscles that had regenerated for 4 or 5 days. D4Z4-2.5 muscle at
day 4 of regeneration showed a significant increase in DUX4 levels
(n=3 mice) and approached significance at day 5 (Fig. 1C), with
control genes Pax7, Myod and Myog generally higher than in
undamaged muscle, as expected. However, DUX4 transcripts could
not generally be detected in either undamaged or regenerating
muscle from control D4Z4-12.5 mice (Fig. 1D,E). Thus, in FSHD1
D4Z4-2.5 mice, DUX4 expression increases transiently during early
muscle regeneration in vivo.
DUX4 is expressed in myoblasts during skeletal muscle
regeneration
To determine if DUX4 is expressed in myoblasts during muscle
regeneration, fluorescence-activated cell sorting (FACS) was
performed in a pilot experiment at day 4 post cardiotoxin
injection – the time point with the highest levels of DUX4
transcripts (Fig. 1C). DUX4 could be detected in RNA pooled from
eight regenerating muscles and the FACS-isolated CD31− CD45−
SCA1− α7-integrin+ population, which was identified as a myoblast
population because they also expressed Pax7, Myod and Myog
(Fig. S1C).
To confirm that DUX4 expression was confined to myoblasts
and not inflammatory cells, FACS was performed to isolate the
CD31− CD45− SCA1− α7-integrin+ population or CD45+ cells
(haematopoetic lineage) from a pool of 14 gastrocnemius muscles
from D4Z4-2.5 mice after 4 days of regeneration. Purity was
confirmed by quantifying gene expression for α7-integrin (Itga7)
and CD45 (encoded by Ptprc) (Fig. 1F,G). DUX4 was largely
confined to the CD45− CD31− SCA1− α7-integrin+ cell population
(Fig. 1H), identified as myoblasts through Pax7, Myod and Myog
expression, but DUX4 was not present in CD45+ cells (Fig. 1H–K).
The λ42/L42 construct (van Deutekom et al., 1993) used to
generate the D4Z4-2.5 transgenicmicewas also transfected intowild-
typemurine satellite cells, and rare DUX4-protein-containing satellite
cells could be identified (Fig. 1L). Thus, the native human contracted
D4Z4 repeat containing 5′ and 3′ regions can be regulated in murine
satellite cells to produce DUX4 protein in vivo and in vitro.
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Fig. 1. See next page for legend.
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The mechanism of action of DUX4
DUX4 that is transcribed from the potential upstream Met-Lys-Gly
(MKG) start site, or from the originally identified Met-Ala-Leu
(MAL) start site, encodes a protein that inhibits myogenic
differentiation and induces cell death (Snider et al., 2009). DUX4c
is identical to DUX4 (MAL start) in the N-terminus and across the
double homeodomain but has an alternative 32-amino-acid C-
terminus. DUX4c and DUX4 proteins lacking the C-terminus inhibit
differentiation but do not induce overt cell death (Ansseau et al.,
2009; Bosnakovski et al., 2008a). Interestingly, the DUX4C-terminal
peptide alone inhibits muscle differentiation (Snider et al., 2009).
We used retroviral expression vectors encoding DUX4, DUX4c
or a truncated DUX4 variant termed tMALDUX4 that initiates at the
MAL start site and is intact across the two homeodomains but
terminates at the Met-Gln-Gly (MQG) site, so lacks the C-terminal
75 amino acids of DUX4 or the 32 amino acids of DUX4c (Snider
et al., 2009). We also used tMALDUX4 fused to a VP16
transactivation domain to generate the constitutively active
tMALDUX4–VP16 construct, or the Engrailed repressor domain
to create the dominant-negative tMALDUX4–ERD construct
(Banerji et al., 2015a) (Fig. 2A).
To assess transcriptional activation of our DUX4 constructs,
we used three DUX4 reporter constructs incorporating the
ZSCAN4, RFPL4b or KHDC1L promoters driving a luciferase
reporter gene (Ferreboeuf et al., 2014). DUX4 constructs and
DUX4 reporters were co-transfected into murine C2C12
myoblasts, together with an RSV-β-galactosidase construct for
normalisation of transfection efficiency. DUX4 and
tMALDUX4–VP16 robustly activated all three DUX4 reporters
compared to transfection with control plasmid, whereas
tMALDUX4, DUX4c or tMALDUX4–ERD did not (Fig. 2B).
tMALDUX4–VP16 activated the ZSCAN4 reporter more than
DUX4, whereas RFPL4b and KHDC1L reporters were activated
to similar extents by both constructs.
DUX4 alters cell morphology and causes apoptosis through
transcriptional activation of target genes
Proteins encoded by each DUX4 construct could be identified in
C2C12myoblast nuclei using the 9A12monoclonal antibody (Dixit
et al., 2007). The viral vector has an IRES-eGFP module to mark
transduced cells (Fig. 2C). C2C12 myoblasts that were transduced
with DUX4 displayed a specific morphological phenotype,
extending long cytoplasmic projections (Fig. 2C), as previously
observed in the iC2C12-DUX4 immortalised cell line (Bosnakovski
et al., 2008b). Expression of tMALDUX4–VP16 also caused long
cytoplasmic projections, but tMALDUX4–ERD, tMALDUX4 or
DUX4c did not perturb morphology, indicating that the projections
are a result of transcriptional activation of target genes.
We next assayed apoptosis in plated satellite-cell-derived primary
myoblasts by measuring caspase 3 and caspase 7 activity over the
48-h period after transduction with retroviruses encoding the DUX4
constructs. Caspase 3 and caspase 7 activity generally increased
over time, as expected (Dee et al., 2002). However, further increased
caspase activity was measured at 36 and 38 h post transduction in
myoblasts expressing DUX4, and in those expressing tMALDUX4–
VP16 at 38 h (Fig. 2D).
DUX4 maintains Pax7 expression through transcriptional
activation of target genes
We first investigated the effects of the DUX4 constructs on early
myogenesis. At 24 h after isolation, extensor digitorum longus
(EDL) satellite cells that were associated with their myofibres were
transduced with either retroviruses encoding DUX4, tMALDUX4,
tMALDUX4–VP16, tMALDUX4–ERD, DUX4c or control
retrovirus, and were cultured for 48 h before immunostaining
(Fig. 3). For illustration, only co-immunostaining for eGFP and
Pax7 (Fig. 3A), eGFP and MyoD (Fig. 3C) or eGFP and myogenin
(Fig. 3E) after transduction with control or retroviral constructs
encoding DUX4 are shown. Similarly, cytoplasmic projections
were observed after DUX4 retroviral infection of satellite cells that
were associated with EDL myofibres (Fig. 3A).
Quiescent satellite cells express Pax7. Upon activation and
differentiation of satellite cells, Pax7 expression decreases, with
the few cells retaining Pax7 thought to be those that repopulate
the stem cell pool (Zammit et al., 2004). A higher proportion of
satellite cells expressing DUX4 and tMALDUX4–VP16 retained
Pax7 (Fig. 3A,B). This suggests that DUX4 inhibits myogenic
progression in satellite cells and causes retention of proteins that are
normally associated with a more naïve stem cell and less-
differentiated phenotype.
DUX4, DUX4c and tMALDUX4 inhibit entry into myogenic
differentiation
Myod expression increases in proliferating satellite cells and drives
the early stages of myogenic differentiation (Zammit et al., 2004).
Expression of DUX4 constructs (except tMALDUX4–ERD)
significantly reduced the proportion of satellite cells that
contained MyoD (Fig. 3C,D).
Satellite cells that have committed to myogenic differentiation
express myogenin (Zammit et al., 2004). DUX4 expression
significantly reduced the proportion of satellite cells containing
myogenin (Fig. 3E,F). DUX4c, tMALDUX4 and tMALDUX4–
ERD also reduced the proportion of myogenin-expressing satellite
cells, but tMALDUX4–VP16 did not (Fig. 3F).
Fig. 1. DUX4 is elevated in transgenic D4Z4-2.5 myoblasts during muscle
regeneration. (A) Gastrocnemius muscles of D4Z4-2.5 mice were injected
with cardiotoxin (CTX), whereas the contralateral muscle received saline, and
analysed with H&E at 3, 4, 5, 6 and 10 days post-injury. (B) RT-qPCR analysis
of humanDUX4 transcribed from the transgenic locus, together withMyod and
Myog, was assessed in D4Z4-2.5 mice at 3, 4, 5, 6 and 10 days post-injury.
(C) Human DUX4, murine Myod and Myog were assessed with RT-qPCR
analysis in gastrocnemius muscle of D4Z4-2.5 mice at day 4 (n=3) and day 5
(n=3) of regeneration. (D,E) HumanDUX4, murineMyod andMyog expression
was assessed in gastrocnemius muscle of control D4Z4-12.5 mice, 4 days
post injury (n=4). (D) DUX4 in control mice could not be quantified, and so
DUX4 products are displayed on a gel (in duplicate), together with reference
genes. (E) Quantification ofMyod andMyog expression in regenerating D4Z4-
12.5 compared to D4Z4-2.5 muscle. Expression was normalized to that in
saline-injected muscle. Data are mean±s.e.m., where an asterisk in C denotes
significant difference (P<0.05) from saline-injected control using a Student’s
t-test. (F–K) Regenerating D4Z4-2.5 gastrocnemius muscle was isolated
4 days after CTX injection from 14D4Z4-2.5 mice. 1.5×106 cells were analysed
with FACS to isolate the CD31− CD45− SCA1− α7-integrin+ population;
5.3×106 cells were analysed for the CD45+ population. Saline: RNA from
saline-injected D4Z4-2.5 gastrocnemius muscles. RNA from complete saline-
injected D4Z4-2.5 gastrocnemius muscle was a negative control, whereas
RNA from CTX-injected D4Z4-2.5 gastrocnemius muscle acted as a positive
control. (F,G) FACS sorting to enrich for CD45− CD31− SCA1− α7-integrin+
cells or CD45+ cells was confirmed by performing RT-qPCR. (H) DUX4 was
largely confined to CD45− CD31− SCA1− α7-integrin+ cells, identified as
myoblasts by (I) Pax7, (J) Myod and (K) Myog expression. Expression values
for genes of interest were normalised to those of the reference genes Tbp
and Rpl13a. Expression was normalized to saline-injected muscles. (L) The
λ42/L42 construct, used to generate D4Z4-2.5 mice, was transfected into
murine satellite cells that were cultured in association with myofibres. At 48 h
post transfection, co-immunostaining revealed rare satellite cells containing
DUX4 and myogenin protein. Scale bar: 20 µm.
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Fig. 2. See next page for legend.
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The reduction in satellite-cell proliferation is due to DUX4
transcriptional activity
To examine the effects of DUX4 during proliferation, we used
expanded primary myoblast cultures, which were transduced with
the DUX4 retroviral constructs and DUX4c, and pulsed with EdU.
There was a reduced proportion of satellite-cell-derived myoblasts
containingEdUafter transductionwithDUX4, tMALDUX4–VP16or
DUX4c constructs, compared to transduction with control retrovirus
(Fig. 4A). The proliferation ratewas unaltered inmyoblasts expressing
tMALDUX4 or tMALDUX4–ERD (Fig. 4A). The nuclear pattern of
the signal after co-labelling with antibodies against phosphorylated
histones H1 and H3 can be used to identify stages of the cell cycle
(Hendzel et al., 1997; Lu et al., 1994). DUX4 expression significantly
reduced the proportion of satellite cells that were in all phases of the
cell cycle and increased the proportion that were in G0 (Fig. 4B).
Activation or inhibition of DUX4 target genes suppresses
myotube formation
We next examined the effects of DUX4 constructs on later phases of
differentiation. Satellite-cell-derived myoblasts were cultured at high
density to mitigate the anti-proliferative effects of some constructs,
transduced with retroviruses encoding DUX4c or DUX4 constructs
and switched to low-serum conditions to promote fusion. Co-
immunostaining for eGFP and myosin heavy chain (MyHC) revealed
that myoblasts that had been infected with control retrovirus readily
formed large multinucleated myotubes (fusion index of ≥2 nuclei/
myotube), which appear yellow-orange in merged images
(Fig. 4C,D). Expression of any of the DUX4 constructs reduced
myoblast fusion, resulting in numerous unfused eGFP-positive
(green) myoblasts. MyHC-positive but eGFP-negative red
myotubes, principally composed of non-transduced myoblasts,
could also be identified (Fig. 4D). However, two categories of
severity were identified: tMALDUX4 or DUX4c had a less-profound
effects on fusion than DUX4, tMALDUX4–VP16 or tMALDUX4–
ERD, with cells even unable to differentiate into unfused myocytes
expressing MyHC in the latter category (Fig. 4C,D). Thus, both
transcriptional activation and suppression of DUX4 target genes
reduces and/or prevents myoblast fusion, whereas loss of the
C-terminus of DUX4 in tMALDUX4 and DUX4c lessens these
inhibitory effects. The effects on satellite cell function of the four
DUX4 constructs and DUX4c are summarised in Fig. 4E.
DUX4 is predominately an activator of transcription
Previous transcriptional profiling of gene expression changes
induced by DUX4 constructs (GEO accession number
GSE77100; http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE77100) has revealed that DUX4 in murine satellite cells
recapitulates a transcriptional signature that has been identified in
human FSHD muscle biopsies (Banerji et al., 2015a).
To investigate whether DUX4 operates solely as a transcriptional
activator, we considered t-values derived from differential expression
analysis of datasetGSE77100by comparing gene expression driven by
DUX4, tMALDUX4, tMALDUX4–VP16, tMALDUX4–ERD and
DUX4c to that with control retrovirus (Fig. 5A). DUX4 and
tMALDUX4–VP16 displayed a strong positive correlation in their
respective transcriptional differential expression values from control
(r=0.835, P<2.2×10−16), showing that DUX4 is a transcriptional
activator (Fig. 5B). tMALDUX4–VP16 and tMALDUX4–ERD had
anti-correlated transcriptional perturbations from control, which is
unsurprising because ERD and VP16 domains mediate inverse
transcriptional responses (r= – 0.087, P<2.2×10−16). Importantly,
DUX4 and tMALDUX4–ERD displayed no correlation in their
transcriptional perturbations from control (r=0.007, P=0.15),
suggesting that DUX4 also suppresses transcription of some target
genes (Fig. 5B).
Transcriptional changes elicited by DUX4c were positively
correlated with those caused by DUX4 (r=0.41, P<2.2×10−16),
indicating overlap in their transcriptional influence (Fig. 5B).
Interestingly, DUX4c-induced transcriptional changes were
significantly positively correlated with those induced by both
tMALDUX4–VP16 (r=0.55, P<2.2×10−16) and tMALDUX4–
ERD (r=0.04, P=3.5×10−12), suggesting that although DUX4c
increases transcription of some genes that are induced by DUX4, it
might also repress a considerable proportion, acting in an
antagonistic manner on the DUX4 phenotype. Finally,
transcriptional changes caused by tMALDUX4 and DUX4c were
highly correlated (r=0.817, P<2.2×10−16) (Fig. 5B), indicating that
the unique 32-amino-acid C-terminus of DUX4c does not
drastically alter its transcriptional profile.
Concordance between DUX4-driven gene expression
changes in mouse and humans
We also performed differential expression analyses using an
empirical Bayes approach employing a P<0.05 significance
threshold (Smyth, 2004) in comparing gene expression in the
presence of DUX4, tMALDUX4, tMALDUX4–VP16,
tMALDUX4–ERD and DUX4c independently to that under
control retrovirus (Fig. 6A). A gene was considered upregulated
by DUX4 if it was upregulated by both DUX4 and tMALDUX4–
VP16 but downregulated by tMALDUX4–ERD, compared to
control (Fig. 6A). A gene was considered downregulated by DUX4
if it was downregulated by both DUX4 and tMALDUX4–VP16 but
upregulated by tMALDUX4–ERD, compared to control (Fig. 6A).
Together, this generated a sample-specific biomarker for DUX4
activity by comparing expression of 291 DUX4-upregulated target
genes to 344 DUX4-downregulated target genes in each sample
(Table S1). DUX4-upregulated target genes should be at higher
levels than downregulated target genes in samples expressing
DUX4; thus, the difference between upregulated and downregulated
target gene distribution is a biomarker for DUX4 expression.
This DUX4 biomarker shows significant concordance in the
genes changed by DUX4 in our microarray using primary mouse
satellite cells and those identified as changed in C2C12 myoblasts
(Bosnakovski et al., 2008b; Sharma et al., 2013) (Fig. 6B,C).
Importantly, this DUX4 biomarker also shows significant
concordance with changes elicited by DUX4 in human cells
(Geng et al., 2012), and can be used to distinguish human myoblasts
Fig. 2. DUX4 changes cell morphology and increases apoptosis.
(A) Schematic showing the DUX4 constructs and DUX4c, together with IRES-
eGFP. (B) Transcriptional activity was assessed in C2C12 myoblasts by co-
transfection of DUX4 constructs and DUX4c with three DUX4-responsive
promoters driving luciferase reporter genes ( pZSCAN4-luc, pKHDC1L-luc or
RFPL4b-luc), together with β-galactosidase for transfection normalisation.
Only DUX4 and tMALDUX4–VP16 strongly activated DUX4 reporters. Boxes
represent the interquartile range (central 50% of data) with the median
indicated by a line, and whiskers indicate the extremes of the distribution.
(C) Retroviral (RV)-mediated expression of DUX4 constructs and DUX4c in
C2C12 myoblasts that had been co-immunostained for eGFP (green) to
identify transduced cells, actin (red) and DUX4 (white, inset panel) with DAPI
(blue). DUX4- and tMALDUX4–VP16-transduced myoblasts had altered
morphology, with long projections (arrows). Scale bars: 20 µm. (D) Apoptosis
was assayed in plated satellite-cell-derived primary myoblasts by measuring
caspase 3 and caspase 7 activity over 48 h post transduction with retroviruses
encoding DUX4 constructs and DUX4c. Data are mean±s.e.m. from three
experiments (B) or four mice (D), where an asterisk denotes significant
difference (P<0.05) from GFP control using a Student’s t-test.
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expressing DUX4 from those expressing either DUX4-s or control
(Fig. 6D).
Using the microarray analysis of human myoblasts that expressed
DUX4 (Geng et al., 2012), we also determined the DUX4
transcription signature in humans comprising 123 upregulated and
253 downregulated genes (Table S2). This human DUX4 signature
clearly separated our DUX4- and tMALDUX4–VP16-expressing
mouse myoblasts from those expressing DUX4c and tMALDUX4
(Fig. 6E), and also those expressing tMALDUX4–ERD from
DUX4c- and tMALDUX4-expressing myoblasts (Fig. 6E). Thus,
genes controlled by DUX4 in mouse overlap with those regulated
by DUX4 in humans.
DUX4 increases transcriptomic measures of stem cells
Signalling entropy is a combined single-sample measure of
intracellular signalling promiscuity and intercellular heterogeneity,
derived from integration of gene expression data with a protein
interaction network. Signalling entropy is a powerful measure of
cell differentiation potential, valid across multiple lineages and in
pathology, and we have shown previously that it outperforms other
popular methodologies (Banerji et al., 2013, 2015b). The
assumption is that stem cells have many options with respect to
fate, and so the diversity of genes expressed is high, giving stem
cells a high signalling entropy. In contrast, differentiated cells have a
more limited and defined gene expression profile in order to perform
Fig. 3. DUX4 inhibits myogenic progression. Satellite cells maintained on their associated myofibres were transduced with retroviruses (RVs) encoding DUX4
constructs, DUX4c or control, and were cultured for 48 h and co-immunostained for eGFP and Pax7, eGFP and MyoD or eGFP and myogenin. (A,C,E) Co-
immunostaining with control and DUX4-encoding retrovirus only, is illustrated. (B) The proportion increased of DUX4 and tMALDUX4–VP16 (eGFP) satellite cells
expressing Pax7. (D) DUX4 and tMALDUX4–VP16 reduced the proportion of cells expressing MyoD. Pax7 (B) and MyoD (D) were unaffected by tMALDUX4–
ERD. (F) DUX4 but not tMALDUX4–VP16 reduced the proportion of cells expressing myogenin. Both tMALDUX4 and DUX4c reduced the proportion of cells with
MyoD (D) and myogenin (F), but only DUX4c affected Pax7 expression (B). Data are mean±s.e.m. from three mice; an asterisk denotes significant difference
(P<0.05) from transduction with control RV using a Student’s t-test. Scale bars: 50 µm.
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their functions, so have low signalling entropy. Thus signalling
entropy progressively drops during progress from stem cells to
differentiated cells, so signalling entropy indicates the position of a
cell population on this spectrum (Banerji et al., 2013).
Computing signalling entropy for each DUX4 construct revealed
that gene expression profiles induced by DUX4 and tMALDUX4–
VP16 displayed significantly higher signalling entropy than those
induced by control (P<0.005) and DUX4c (P<0.0006), suggesting
that DUX4 results in a transcriptomic profile that is more like that of
a stem cell or of a less-differentiated cell (Fig. 6F). In contrast,
tMALDUX4–ERD displayed a significantly lower signalling
entropy than control (P<0.04), suggesting that repression of
DUX4 target genes causes a more differentiated expression
regime. tMALDUX4- and DUX4c-expressing cells had similar
signalling entropy to that of control cells (Fig. 6F), suggesting that
they do not significantly alter global transcriptomic measures of
differentiation potential, despite their effects on key markers of
differentiation at the protein level (Figs 3 and 4).
DUX4 regulates genes associated with apoptosis and
reduced cell proliferation
DUX4 principally activates transcription of target genes, whereas
DUX4c and tMALDUX4 activate some of these DUX4 target
genes but repress others. We compared pathways that are regulated
by DUX4 and DUX4c using sequential gene-set filtering and
information from the four DUX4 construct and DUX4c microarrays
Fig. 4. DUX4 reduces myogenic
fusion by both transcriptional
activation and suppression of target
genes. Expanded satellite-cell-derived
myoblasts were transduced to express
DUX4, tMALDUX4, tMALDUX4–VP16,
tMALDUX4–ERD, DUX4c or control
retrovirus (RV). (A) At 24 h post-
transduction, myoblasts were pulsed
with EdU for 2 h, fixed and
immunostained for eGFP with EdU
detection. DUX4, tMALDUX4–VP16 or
DUX4c expression reduced the
proportion of eGFP+ myoblasts
containing EdU. (B) The pattern of
phosphorylated histones H1 and H3
immunosignal can be used to identify
stages in the cell cycle (Hendzel et al.,
1997; Lu et al., 1994) and revealed that
DUX4 suppressed cell cycle
progression. (C,D) Transduced
myoblasts were switched to
differentiation medium for 48 h, and co-
immunostained for eGFP (green) and
MyHC (red) with DAPI counterstain
(blue). (C) DUX4 constructs and DUX4c
significantly reduced the fusion index
(≥2 nuclei). (D) DUX4 constructs
reduced the number and size of
myotubes, with many unfused eGFP+
and MyHC− myoblasts. Data are mean
±s.e.m. from three mice, where an
asterisk denotes significant difference
(P<0.05) from transduction with control
RV using a paired Student’s t-test. Scale
bars: 50 µm. (E) Summary of effects of
DUX4 constructs and DUX4c on satellite
cells.
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(Fig. 6A). In addition to the target gene set that acts as a DUX4
biomarker, we also generated two DUX4c target gene sets – one in
which genes were considered to be upregulated by DUX4c if they
were upregulated by both tMALDUX4 and DUX4c, and one in
which genes were considered to be downregulated by DUX4c if
they were downregulated by both tMALDUX4 and DUX4c
(Fig. 6A). Gene set enrichment analysis was used to evaluate
whether genes that were commonly and differentially regulated by
DUX4 and DUX4c (Table S3) were significantly associated with
particular functional classes. After correcting for multiple testing,
there was no enrichment for gene sets that were downregulated by
both DUX4 and DUX4c or that were upregulated by DUX4 but not
DUX4c (Tables S4 and S5).
Crucially, genes downregulated by DUX4 but not DUX4c were
significantly enriched for those regulating cell proliferation and
apoptosis, for example those encoding TGFβ1 and Notch1 (Fig. 7A;
Table S6). Genes upregulated by both DUX4 and DUX4c were
significantly enriched for urogenital development and gland
development, for example Gata3, Esr1, Bcl2 and Wwtr1 (Fig. 7B;
Table S7). Genes that were upregulated by DUX4c but not
DUX4 were strongly associated with angiogenesis and blood vessel
morphogenesis, for example Hey1 (Fig. 7C; Table S8). Conversely,
genes downregulated by DUX4c but not DUX4 were associated
with developmental processes and muscle development, for
example Hoxa1, Fzd2, Tnnc2, Myh7 and myoglobin (Mb) (Fig. 7D;
Table S9).
DISCUSSION
DUX4 plays a key role in FSHD1 and FSHD2 pathology because of
its de-repression in skeletal muscles (Tawil et al., 2014). Epigenetic
regulation of the D4Z4 repeat in transgenic D4Z4-2.5 mice is
generally similar to that in man, with variable low levels of DUX4 in
Fig. 5. DUX4 acts by both activating and
suppressing target genes. (A) Flow chart describing
the filtering of probes to identify genes whose
expression was modified by DUX4 constructs and
DUX4c. (B) Global transcriptomic analysis of
microarray assays of cells expressing DUX4 constructs
(compared to control) demonstrates correlations
between differential expression t-values. Positive
correlations were detected between DUX4 and
tMALDUX4–VP16 gene sets and between DUX4 and
DUX4c gene sets. Lack of anti-correlation between
DUX4 and tMALDUX4–ERD gene sets indicates that
DUX4 also suppresses transcription of some target
genes.
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Fig. 6. DUX4 induces signatures of a stem-cell-like and less-differentiated state. (A) Transcripts that were upregulated (red) by DUX4 and tMALDUX4VP16
(tDUX4VP16) but downregulated (green) by tMALDUX4ERD (tDUX4ERD) were considered as positively correlated (upregulated) with DUX4 activity.
Conversely, transcripts that were downregulated (green) by DUX4 and tMALDUX4VP16 but upregulated (red) by tMALDUX4ERD were considered as negatively
correlated (downregulated) with DUX4 activity. Transcripts upregulated (red) by tMALDUX4 and DUX4c were considered as positively correlated (upregulated)
with DUX4c activity. Conversely, transcripts downregulated (green) by tMALDUX4 and DUX4c were considered as negatively correlated (downregulated) with
DUX4c activity. (B–D)We constructed a single-sample DUX4 expression score from our study in mouse to examine overlap with DUX4 target genes identified by
other studies. (B,C) Our mouse DUX4 expression score distinguishes murine C2C12 myoblasts expressing DUX4 from controls in two independent published
microarray studies (Bosnakovski et al., 2008b; Sharma et al., 2013). (D) Our mouse DUX4 expression score also distinguishes DUX4-expressing human
immortalised myoblasts from those expressing DUX4-s or eGFP control (Geng et al., 2012). (E) A human DUX4 signature derived from human myoblasts
expressing DUX4 (Geng et al., 2012) distinguishes mouse myoblasts expressing tMALDUX4 and DUX4c both from those expressing DUX4 or tMALDUX4–
VP16, and also from those expressing tMALDUX4–ERD. (F) Signalling entropy is elevated in the transcriptional profiles induced by DUX4 and tMALDUX4–VP16
but is reduced by tMALDUX4–ERD expression, supporting the hypothesis that DUX4 inhibits myogenic differentiation. Boxes represent the interquartile range
(central 50% of data) with the median indicated by a line, and whiskers indicate the extremes of the distribution. P-values were calculated using Student’s t-test.
RV, retrovirus.
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Fig. 7. GSEA reveals pathways
regulated by DUX4 and DUX4c.
(A) GSEA for genes downregulated by
DUX4 but not DUX4c, with RT-qPCR
validation for genes encoding Notch 1
and TGFβ1, relative to Tbp expression.
(B) GSEA for genes upregulated by
both DUX4 and DUX4c with RT-qPCR
validation for Gata3, Esr1, Bcl2 and
Wwtr1, relative to Tbp expression.
(C) GSEA for genes upregulated by
DUX4c but not by DUX4, with RT-
qPCR validation for Hey1, relative to
Tbp expression. (D) GSEA for genes
downregulated by DUX4c but not by
DUX4, with RT-qPCR validation for
Hoxa1, Fzd2, Tnnc1, Myh7 and Mb
(myoglobin). Data are mean±s.e.m.
using myoblasts from four mice, where
an asterisk denotes significant
difference from control using a paired
Student’s t-test (P<0.05). RV,
retrovirus.
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skeletal muscle, but the transgenic model has no overt muscle
pathology (Krom et al., 2013). Here, we show thatDUX4 expression
increases during muscle regeneration, being expressed by
myoblasts, although overall, DUX4 levels remained low. Our
observations are consistent with those made in primary FSHD
myoblasts, where both DUX4 and its transcriptional activity can be
detected in proliferating and differentiating human myoblasts (Dixit
et al., 2007; Jones et al., 2012; Kowaljow et al., 2007; Rickard et al.,
2015; Snider et al., 2010). Mice have an impressive regeneration
capacity, and so low DUX4 levels or expression restricted to a few
myoblasts might explain the lack of an overt muscle phenotype. The
DUX4 locus is predisposed to being expressed and is activated by,
amongst other things, myogenic transcriptional regulators.
Recently, two myogenic enhancers have been identified (Himeda
et al., 2014), one of which, the DUX4 myogenic enhancer 1
(DME1), is included in the D4Z4-2.5 transgene.
DUX4 splice variants emanate from the D4Z4 repeat array
(Snider et al., 2009), and inappropriate temporal expression or
increased proportions of the transcript encoding DUX4-fl are
probably pathogenic in FSHD muscle. DUX4-fl and splice variants
inhibit myoblast differentiation (Bosnakovski et al., 2008b; Snider
et al., 2009), and DUX4-fl is also apoptotic (Bosnakovski et al.,
2008b; Mitsuhashi et al., 2013; Wallace et al., 2010). DUX4-fl
contains double homeobox DNA-binding domains and an
evolutionarily conserved peptide sequence at the C-terminus
(Clapp et al., 2007) that acts as a strong transcriptional activation
domain (Kawamura-Saito et al., 2006). To better understand the
mode of action of DUX4 and DUX4c on myogenesis, we used our
panel of four DUX4 constructs, including constitutively active,
dominant-negative and truncated versions of DUX4.
Pax7 is expressed in activated satellite cells, but levels decrease
during differentiation, with Pax7 and myogenin expression
being mutually exclusive (Zammit et al., 2004). DUX4 and
tMALDUX4–VP16 resulted in maintenance of Pax7 expression,
as did DUX4c, whereas transcriptional repression of target genes
by the tMALDUX4–ERD construct did not alter Pax7 levels.
DUX4, tMALDUX4 and DUX4c also reduced Myod expression.
Because tMALDUX4–VP16 but not tMALDUX4–ERD reduced
Myod levels, it is likely that DUX4 activates genes involved inMyod
repression rather than by directly repressing Myod transcription
itself, providing insight into MYOD-dependent pathway
suppression in FSHD (Celegato et al., 2006; Winokur et al., 2003b).
Interestingly, the C-terminal peptide of DUX4 inhibits myogenin
expression in the absence of the DNA-binding homeodomains
(Snider et al., 2009). tMALDUX4–VP16 does not contain this
C-terminal peptide and did not alter myogenin gene expression,
showing that DUX4 is not solely acting by transcriptionally activating
target genes, consistent with observations that tMALDUX4–ERD
also suppresses myogenin.Myf5 mRNA is upregulated by DUX4 in
immortalised myoblasts and satellite cells (Banerji et al., 2015a;
Bosnakovski et al., 2008b) and this could represent a compensatory
mechanism.However, DUX4 inhibits bothMyod andmyogenin gene
expression in mouse satellite cells to produce a differentiation defect
that cannot be overcome by upregulation ofMyf5.
All DUX4 constructs and DUX4c inhibited myoblast fusion into
multinucleated myotubes, but DUX4c and tMALDUX4 had
relatively mild effects. Myoblasts were re-plated at high-density
before assessing fusion, to mitigate the effects on proliferation.
However, tMALDUX4–ERD did not affect proliferation yet still
blocked fusion, indicating that transcriptional activation of DUX4
target genes inhibits proliferation, but both activation and
suppression of target genes can suppress differentiation.
Thus, DUX4 expression results in maintenance of a stem-cell-like
and less-differentiated state, with concomitant suppression of
proliferation and inhibition of differentiation. This striking
differentiation defect might explain the lack of muscle phenotype
in our D4Z4-2.5 mice because rare DUX4-expressing myoblasts
might be inhibited from fusing into myofibres.
To better understand DUX4, we further analysed our microarray
of satellite-cell-derived myoblasts expressing DUX4, tMALDUX4–
VP16, tMALDUX4–ERD, tMALDUX4 or DUX4c constructs
(Banerji et al., 2015a). Pairwise comparison of the transcriptional
changes caused by each construct compared to control allowed us to
determine the predominant mode of action of DUX4.
Transcriptional changes elicited by DUX4 or tMALDUX4–VP16
were strongly positively correlated, indicating that DUX4 activates
many transcriptional targets. Interestingly, although DUX4 and
tMALDUX4–VP16 had very similar transcriptome signatures, they
were not identical, indicating that DUX4 is not operating solely as a
transcriptional activator. Indeed, although the expression profile of
tMALDUX4–VP16 target genes was anti-correlated to that of
tMALDUX4–ERD, DUX4 was not, indicating that DUX4 also
suppresses some transcriptional target genes. The target gene sets of
tMALDUX4 and DUX4c were positively correlated, but were also
positively correlated with DUX4, indicating that they have many
target genes in common. This again suggests additional mechanisms
by which DUX4 alters transcriptional regulation that are distinct
from the activity of its C-terminal transactivation domain.
Signalling entropy is a strong correlate of differentiation potential
in healthy tissue (Banerji et al., 2013) and is a powerful prognostic
factor in cancerous tissue, where it is associated with anaplasia
(Banerji et al., 2015b). tMALDUX4 or DUX4c induced
similar signalling entropies to control, whereas tMALDUX4–ERD
decreased signalling entropy, indicating induction of differentiation.
In contrast, signalling entropywas raised byDUX4 or tMALDUX4–
VP16, implying that DUX4 activates transcriptional target genes
that are expressed in stem cell populations, consistent with retention
of Pax7 expression in satellite cells.
Although there are Dux-like genes in mouse, there is debate about
how useful mouse studies are for identifying genes regulated by
DUX4. However, there has only been limited assessment of the
concordance in mouse and man between DUX4-mediated
transcriptional changes. There was a 27% overlap of transcripts that
are differentially expressed by DUX4 in mouse C2C12 myoblasts
compared to human RD rhabdomyosarcoma cells expressing DUX4,
despite effects associated with comparing mouse myoblasts with
human cancer cells (Sharma et al., 2013). We have also demonstrated
previously a 23% overlap in DUX4 targets between mouse and man
using the transgenic D4Z4-2.5 mouse model (Krom et al., 2013).
However, the significance of this overlap in DUX4-perturbed genes
was not statistically assessed in these studies.
Objectively assessing mouse as a FSHD model is requisite
because many mouse models have been developed for FSHD (Lek
et al., 2015). Reliable transcriptomic profiling of DUX4
overexpression requires matched cell types between mouse and
man, and statistical assessment of target overlap. We developed a
DUX4 signature of genes using our microarray in primary mouse
satellite cells. Our mouse DUX4 signature could distinguish mouse
C2myoblasts expressing DUX4 from control cells, described in two
independent studies (Bosnakovski et al., 2008b; Sharma et al.,
2013). Importantly, this overlap extended to a human microarray
study (Geng et al., 2012), where genes identified as being perturbed
by DUX4 in our murine myoblasts could also be used to distinguish
human myoblasts overexpressing DUX4 from those expressing
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DUX4-s or eGFP controls. We also derived a human DUX4
signature, which separated our DUX4- and tMALDUX4–VP16-
expressing mouse myoblasts from those expressing DUX4c and
tMALDUX4, and also tMALDUX4–ERD-expressing cells from
those expressing DUX4c and tMALDUX4. Thus, there is a
statistically significant overlap in DUX4 transcriptional
dysregulation across mouse and man. Furthermore, DUX4 in mouse
primary myoblasts perturbs expression of genes that are modified in
multiple human FSHD muscle biopsies (Banerji et al., 2015a).
Using transcriptome data from mouse satellite cells expressing
DUX4 or tMALDUX4–VP16, we isolated genes that are likely to
be transcriptionally activated by DUX4. Identifying those genes
that exhibited inverse expression patterns in satellite cells
expressing tMALDUX4–ERD increases the confidence that they
are pathways regulated by DUX4. However, DUX4c or DUX4
splice variants also perturb myoblast function (Ansseau et al.,
2009; Bosnakovski et al., 2008b; Snider et al., 2009). Using the
four DUX4 constructs and DUX4c, we filtered gene expression
profiles to provide sets of genes that are perturbed by DUX4 and/or
DUX4c. As expected, those genes regulated by DUX4 but not
DUX4c were enriched for genes involved in apoptosis and
proliferation, consistent with observations that DUX4, but not
DUX4c, is pro-apoptotic in myoblasts. DUX4c-enriched genes
were involved in vascular development, which is relevant given an
association with Coat’s like retinopathy and FSHD (Fitzsimons,
2011). DUX4c-perturbed genes are also involved in muscle
development, supporting an active role for DUX4c in FSHD
muscle pathology (Ansseau et al., 2009). Both DUX4 and DUX4c
regulate genes expressed during urogenital and glandmorphogenesis,
supportingDUX4 expression in testes and indicating that overlapping
DUX4 and DUX4c transcriptional targets could guide development
of urogenital organs (Snider et al., 2010). Finally, genes
downregulated by DUX4c but not DUX4 were associated with
muscle development and axonal guidance. Both DUX4 and DUX4c
inhibit myoblast fusion, whereas DUX4 overexpression in embryonic
stem cells promotes differentiation towards the neuronal lineage
(Dandapat et al., 2014), indicating that DUX4c is associated with
neuronal and myogenic development in a manner that is independent
ofDUX4. These transcriptome signatures add to our understanding of
how DUX4 and DUX4c induce pathology in FSHD. Examining
multiple DUX4 constructs also allows for the identification of target
genes that could be overlooked when examining DUX4 alone due to
its effects on proliferation and apoptosis.
Overall, our study suggests that induction of a more a stem-cell-
like and less-differentiated state in myoblasts expressing DUX4
inhibits proliferation and myogenesis. Identification of pathways
perturbed by DUX4 contributes to the challenge to identify viable
therapeutic targets to alleviate the consequences of mis-expression
of DUX4 in FSHD.
MATERIALS AND METHODS
Muscle injury
Procedures were carried out under the Animals (Scientific Procedures)
Act 1986, as approved by King’s College London Ethical Review
Process committee or approved by the local animal experimental
committee of Leiden University Medical Center and by the
Commission Biotechnology in Animals of the Dutch Ministry of
Agriculture. Four-month-old hemizygous D4Z4-2.5 and D4Z4-12.5
mice were used (Krom et al., 2013). Muscle injury was induced by
intra-muscular injection of 10 μM cardiotoxin in 50 μl PBS into the
gastrocnemius of anaesthetised mice. Contra-lateral muscles were injected
with 50 μl saline. Muscles were isolated at days 3, 4, 5, 6 and 10 post-
cardiotoxin, snap-frozen in 2-methylbutane (Sigma-Aldrich, Dorset, UK)
cooled in liquid nitrogen, cryosectioned and stained with haematoxylin
and eosin (H&E). D4Z4-2.5 (stock #027991) and D4Z4-12.5 (stock
#028012) transgenic mice are available from the Jackson Laboratory.
qPCR
RNAwas isolated using miRNeasy kit (Qiagen, Manchester, UK) including
DNase digestion. Tissues were homogenised in 700 μl qiazol and
resuspended in 700 μl qiazol. RNA quality and concentration were
checked by using a LabChip Bioanalyzer (Agilent) and Nanodrop (ND-
1000 spectrophotometer, Thermo Fisher Scientific). cDNA synthesis was
performed with 3 μg RNA using Revert Aid H minus first strand cDNA
synthesis kit (Thermo Fisher Scientific) and oligo dT primers
(Thermo Fisher Scientific). Control comprised no RevertAid H minus
M-MulV and Ribolock RNase inhibitor samples. SYBR-Green-based
real-time PCR (96°C for 6 min, 40 cycles at 95°C for 10 s, 60°C for 30 s,
95°C for 10 s, followed by melt curve analysis) on a CFX96 system
(BioRad, Hertfordshire, UK). Primers were designed using Primer3
software: DUX4-Fw, 5′-CCCAGGTACCAGCAGACC-3′, Rev, 5′-CCC-
AGGTACCAGCAGACC-3′; Myog-Fw, 5′-CCTTGCTCAGCTCCCTCA-
3′, Rev, 5′-TGGGAGTTGCATTCACTGG-3′; MyoD-Fw, 5′-TA-CAGT-
GGCGACTCAGATGC-3′, Rev, 5′-TAGTAGGCGGTGTCGTAGCC-3′;
α7-integrin (Itga7)-Fw, 5′-CCTGGAAGTGATCGTCCGAG-3′, Rev,
5′-CCATGGGGTCCAAGTACACC-3′; Ptprc (Cd45)-Fw, 5′-CCTGCA-
GAACCCAAAGACCT-3′, Rev, 5′-CCTGTCTGCTGGGATCCATC-3′;
Duxbl-Fw, 5′-GCATCTCTGAGTCTCAAATTATGACTTG-3′, Rev,
5′-GCGTTCTGCTCCTTCTAGCTTCT-3′; Tbp-Fw, 5′-CTCAGTTACA-
GGTGGCAGCA-3, Rev, 5′-CAGCACAGAGCAAGCAACTC; RPL13a-
Fw, 5′-GCTGCTCTCAAGGTTGTTC-3′, Rev, 5′-TTCTCCTCCAGAG-
TGGCTGT-3′;Notch1-Fw, 5′-TCAATGTTCGAGGACCAGATG-3′, Rev,
5′-TCACTGTTGCCTGTCTCAAG-3′; Tgfb1-Fw, 5′-CCCTATATTTGG-
AGCCTGGA-3′, Rev, 5′-CTTGCGACCCACGTAGTAGA-3′; Hey1-Fw,
5′-TACCCAGTGCCTTTGAGAAG-3′, Rev, 5′-AACCCCAAACTCCG-
ATAGTC-3′; Tnnc2-Fw, 5′-CGAGGATGGCAGCGGTACTA-3′, Rev,
5′-CCTTCGCATCCTCTTTCATCTG-3′; Myh7-Fw, 5′-CCAAGAAGG-
CTATCACAGATGC-3′, Rev, 5′-TTCCTGTCTTCCTCTGTCTGGT-3′;
Mb-Fw, 5′-GGCAGCTGGTGCTGAATGT-3′, Rev, 5′-TAAACAGACC-
GATGAGGACTTCCT-3′; Fzd2-Fw, 5′-TCGCCTACAACCAGACCATC-
3′, Rev, 5′-CATTGGAAGCCGAACTTGT-3′; Hoxa1-Fw, 5′-CTTCTCC-
AGCGCAGACCTT-3′, Rev, 5′-CTGTGAGCTGCTTGGTGGT-3′; Gat-
a3-Fw, 5′-TTTACCCTCCGGCTTCATCCTCCT-3′, Rev, 5′-TGCAC-
CTGATACTTGAGGCACTCT-3′; Esr1-Fw, 5′-GCACAGGATGCTAG-
CCTTGTCTC-3′, Rev, 5′-CCAGCTTGCAGGTTCATTGTG-3′; Bcl2-Fw,
5′-TGAGTACCTGAACCGGCATCT-3′, Rev, 5′-GCATCCCAGCCTCC-
GTTAT-3′;Wwtr1-Fw, 5′-GCCACTGGCCAGAGATACTT-3′, Rev, 5′-G-
ACGGGTGGAGGTTCACAT-3′.
FACS
Gastrocnemius muscles were isolated four days after cardiotoxin injection.
Two control and two cardiotoxin-injected muscles were frozen to assess
DUX4 levels. For FACs, cardiotoxin-injected muscles were minced and
digested in 1.2 units/ml dispase II, 2 mg/ml collagenase type IV
(Worthington) and 2 mM CaCl2 in PBS for 45 min at 37°C. Enzymes
were neutralised with HAM’S/F10 with 15% horse serum and passed
through a 70-µm then 40-µm nylon cell strainer (BD Falcon, Oxfordshire,
UK). Samples were centrifuged at 300 g for 5 min and the pellet was re-
suspended in haemolytic buffer (155 mM NH4Cl, 10 mM KHCO2 and
0.1 mM EDTA) for 5 min at room temperature before centrifugation at
300 g for 5 min. The pellet was resuspended in 6 ml PBS with 0.5% BSA.
Cells were immunostained with anti-CD45 Alexa-Fluor-700-conjugated
antibody (eBioscience, Hertfordshire, UK), anti-CD31 PE-cyanine-7-
conjugated antibody (eBioscience), anti-SCA1 efluor605NC-conjugated
antibody (eBioscience), anti-α7-integrin FITC-conjugated antibody (R&D
Systems, Oxfordshire, UK) and diluted in 100 µl PBS with 0.5% BSA per
106 cells for 45 min on ice and washed twice in PBS with 0.5% BSA with
centrifugation between washes. Cells were resuspended in 1.5 ml PBS with
0.5% BSA, filtered and stored on ice. 5.3×106 CD45+cells and 1.5×106
CD31− CD45− SCA1− α7 integrin+ cells were analysed by FACS with an
AriaIII FACS instrument and centrifuged at 400 g for 15 min at 4°C.
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Myofibres and satellite cells
C57BL/10 male mice (6–8 weeks) were killed, and EDL muscles were
dissected, and myofibres liberated by enzymatic digestion (Moyle and
Zammit, 2014). Myofibres with their associated satellite cells were
transferred to 5% BSA (Sigma-Aldrich) coated dishes and cultured at
37°C with 5% CO2 in DMEM Glutamax (Thermo Fisher Scientific) with
10% horse serum (v/v) (Gibco), 0.5% chick embryo extract (CEE) (v/v) and
1% penicillin-streptomycin (v/v) (Sigma-Aldrich).
Satellite-cell-derived myoblast preparation
Myofibreswere plated at∼100 fibres/well in 6-well plates coatedwith1 mg/ml
Matrigel (Collaborative Research). Muscle fibres were cultured in medium
comprising DMEMGlutamax (Thermo Fisher Scientific) with 30% foetal
bovine serum (FBS) (v/v), 10% horse serum, 1% CEE, 10 ng/ml basic
fibroblast growth factor (Peprotech, London, UK), 1%penicillin-streptomycin
at 37°C with 5% CO2 for 72 h. Myofibres were removed and myoblasts
expanded for 48 h. To induce differentiation, myoblasts were cultured in
DMEMGlutamax with 2% HS (v/v) and 1% penicillin-streptomycin (v/v).
DUX4 constructs
DUX4, DUX4c, tMALDUX4, tMALDUX4–VP16 and tMALDUX4–ERD
were encoded in pMSCV-IRES-eGFP (Banerji et al., 2015a). An IRES
preceding eGFP allows independent translation to identify transduced cells.
All constructs were sequenced.
Retrovirus was produced by co-transfecting pMSCV-IRES-eGFP DUX4
cDNA’s and an ecotropic helper plasmid into HEK293T using
Lipofectamine (ThermoFisher Scientific). pMSCV-IRES-eGFPwas control.
Retroviral transduction
Myofibres maintained in DMEMGlutamax with 10% horse serum (v/v),
0.5% CEE (v/v) and 1% penicillin-streptomycin (v/v) in 5%-BSA-coated 6-
well plates at 37°C, 5% CO2 for 24 h before transduction. Non-adherent
myofibresweremaintained at 37°C 5%CO2 for 24 or 48 h post-transduction.
Satellite-cell-derived myoblasts were re-plated at 1.5×105 cells perMatrigel-
coatedwell of a 6-well plate (Collaborative Research). Cells weremaintained
in high-serummedium for 24 h beforemedium replacement and transduction
1 h later. Cells were incubated at 37°C 5%CO2 with retrovirus for 4 h before
medium replacement to DMEMGlutamax with 30% FBS (v/v), 10% horse
serum, 1%CEE, 1% penicillin-streptomycin. After 24 h, cells were re-plated
at 5×103 (for proliferation) or 2.5×104 (for differentiation) cells/well in
Matrigel-coated chamber slides.
Immunostaining
Myofibres andmyoblastswere fixed in 4%paraformaldehyde, permeabilised
in 0.5% Triton-X (Sigma-Aldrich) for 10 min, washed with PBS then
blocked for 30 min in 5% (v/v) swine and goat serum (DakoCytomation
Glostrup, Denmark), incubated in primary antibodies overnight at 4°C
[mouse anti-DUX4 antibody [9A12 mAb, a kind gift from Alexandra
Belayew (University of Mons, Mons, Belgium), 1:2000], mouse anti-Pax7
antibody [AB528428, Developmental Studies Hybridoma Bank (DSHB);
1:20–1:100], mouse anti-MyoD antibody clone 5.8A (M3512,
DakoCytomation; 1:50), mouse anti-myogenin antibody (F5D, DSHB;
1:15–1:50), mouse anti-MyHC antibody (MF20, DSHB; 1:400), rabbit anti-
GFP antibody (A-11122, Thermo Fisher Scientific; 1:1000), rabbit anti-
phospho-histone-H1 (06-597, Millipore, 1:300) and anti-phospho-histone-
H3 antibodies (06-570, Millipore; 1:100). After washing, incubation for 1 h
at room temperature with Alexa-Fluor-conjugated secondary antibodies
(Thermo Fisher Scientific) (Moyle and Zammit, 2014).
Images were acquired on a Zeiss Axiovert 200 M microscope using a
Zeiss AxioCamHRm and AxioVision version 4.4 (Zeiss) or a Zeiss
Axioplan 2 with a Hamamatsu ORCA-ER camera with Openlab 3.1.7.
EdU incorporation
Myoblasts were plated at 5×103 in 8-well Matrigel-coated chamber slides,
maintained in high-serum medium for 24 h before transduction, and 24 h
later, pulsed with EdU for 2 h (Thermo Fisher Scientific) and immunostained
for eGFP before EdU detection with Alexa-Fluor-594 (Thermo Fisher
Scientific).
Reporter gene assay
C2C12 myoblasts were co-transfected using Lipofectamine LTX
(Thermofisher) with DUX4c or DUX4 constructs or control GFP and
DUX4-responsive promoters driving luciferase ( pZSCAN4-luc, pKHDC1L-
luc, RFPL4b-luc), together with a pRSV-β-galactosidase construct to
normalise transfections. Myoblasts were harvested 24 h later, and assayed
using the Dual-light Reporter system (Thermofisher) in three transfections
measured in triplicate on a Glomax-Multi+ plate reader (Promega).
Apoptosis assay
Transduced myoblasts were plated (5×103/well) into 96-well plates for
fluorescence assays (Greiner Bio-One) in three technical replicates to
investigate apoptosis using the Caspase-Glo 3/7 Assay (Promega) on a
Glomax-Multi+ microplate reader (Promega). Luminescence activity from
the Caspase-Glo assay from each well was normalised to GFP measured
using the Glomax-Multi+ reader.
Statistical analysis
Myofibre and satellite-cell-derived myoblasts were obtained from at least
three mice. Data from immortalised myoblast lines was from at least three
experiments. Data are mean±s.e.m. with significance assessed by Student’s
t-test, unless otherwise stated.
DUX4 microarray analysis
GSE77100 microarray is available from http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE77100 (Banerji et al., 2015a). Acquisition and
normalisation of these microarray data has been previously described
(Banerji et al., 2015a). Briefly, expanded satellite-cell-derived myoblasts
from three male 8-week-old C57BL/10 mice were transduced with
retroviruses encoding DUX4, DUX4c, tMALDUX4, tMALDUX4–VP16,
tMALDUX4–ERD or control pMSCV-IRES-eGFP with 4 mg/ml
polybrene for 20 h. RNA was extracted using Qiagen RNeasy Kit and
quantified. Gene expression analysis was performed using GeneChip
Mouse Gene 1.0STArray and GCS3000 microarray system (Affymetrix) by
the King’s Genomic Centre.
Differential expression analysis was performed using an empirical
Bayes approach (Smyth, 2004) to identify transcripts perturbed by each
DUX4 construct, t-statistics for transcripts were correlated between
constructs to ascertain similarities in expression landscapes. t-values
described in reference to differential expression are the test statistics of a
standard statistical assessment of differential expression using the Linear
Models for Microarrays (limma) package in R (Smyth, 2004). Transcripts
were filtered using all constructs to obtain two lists representing genes
whose expression was modified by either DUX4 or DUX4c. P<0.05 was
used to identify genes which were differentially expressed by each DUX4
construct compared to control. Expression of genes was then attributed as
DUX4 upregulated if they were upregulated by both DUX4 and
tMALDUX4–VP16 and downregulated by tMALDUX4–ERD.
Expression of genes was attributed as DUX4 downregulated if they were
downregulated by both DUX4 and tMALDUX4–VP16 and upregulated by
tMALDUX4–ERD. Similarly, a gene was considered to be up- or
downregulated by DUX4c if it was up- or downregulated by both DUX4c
and tMALDUX4.
GSEA was performed using a Fisher’s Exact test, using the DAVID
functional annotation tool (Huang et al., 2009a,b). Gene sets which
displayed Benjamini–Hochberg adjusted P<0.05 were considered enriched.
Signalling entropy
Signalling entropy was computed using a mass action principle
approximation (Banerji et al., 2013). Each sample was integrated with a
protein interaction network (PIN) to create a sample specific stochastic
matrix, P=(pij). The PIN was constructed from previous work (Banerji
et al., 2015b) through orthology relations. The ith row of P defines a
probability distribution describing rates of reaction of protein i with each of
its neighbours. Distributions were constructed appealing to a mass action
principle, namely that rate of a reaction is proportional to the product of the
active masses. Assuming log normalised gene expression is a proxy for
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protein concentration, we compute:
pij ¼
Ej=
P
k[NðiÞ
Ek if j [ NðiÞ
0 else
(
;
where Ej is log-normalised expression of gene j in the given sample and N(i)
denotes the set of direct interaction partners of gene i in the PIN. From this
definition,∑jɛN(i)Pij=1 for all j – i.e.P is row stochastic and ith row corresponds
toweighted interaction distribution of protein i in sample. Not all proteins in the
PIN have a corresponding microarray probe, consequentially the PIN is the
maximally connected component after removal of missing proteins.
For each protein i, we define the local entropy of its interaction
distribution, Si, quantifying promiscuity in its signalling within the sample:
Si ¼ 
X
j[NðiÞ
PijlogðPijÞ:
Signalling entropy is a global measure of signalling promiscuity and is
computed from the stochastic matrix pij as the entropy rate (SR) of the
stochastic process described by pij:
SR ¼
X
i
piSi;
where πi denotes the stationary distribution of the stochastic matrix,
satisfying:
X
i
piPij ¼ pj:
πi is the non-degenerate eigenvector of P corresponding to eigenvalue 1. By
Perron–Frobenius existence of πi requires that matrix P be irreducible; as the
PIN considered is connected and non-bipartite, this is guaranteed. R-scripts
for signalling entropy can be found at www.sourceforge.net/projects/
signalentropy.
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